TM-Score predicts immunotherapy efficacy and improves the performance of the machine learning prognostic model in gastric cancer.

doi:10.1016/j.intimp.2024.112224

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

TM-Score predicts immunotherapy efficacy and improves the performance of the machine learning prognostic model in gastric cancer.

International immunopharmacology - 15 Jun 2024

Xiang Kanghui, Zhang Minghui, Yang Bowen, Liu Xu, Wang Yusi, Liu Hengxin, Song Yujia, Yuan Yonghui, Zhang Lingyun, Wen Ti, Zhang Guang-Wei

Abstract excerpt

Immunotherapy is becoming increasingly important, but the overall response rate is relatively low in the treatment of gastric cancer (GC). The application of tumor mutational burden (TMB) in predicting immunotherapy efficacy in GC patients is limited and controversial, emphasizing the importance of optimizing TMB-based patient selection. By combining TMB and major histocompatibility complex (MHC) related hub...

Read the complete abstract on PubMed